bluebird bio (NASDAQ:BLUE) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE) in a report issued on Friday. The firm issued a sell rating on the biotechnology company’s stock.

A number of other analysts have also weighed in on BLUE. JPMorgan Chase & Co. lowered shares of bluebird bio from an “overweight” rating to a “neutral” rating in a research note on Thursday, August 15th. Royal Bank of Canada reissued a “sector perform” rating and set a $4.00 price target on shares of bluebird bio in a research report on Thursday, August 15th. Robert W. Baird lowered their price objective on bluebird bio from $7.00 to $6.00 and set an “outperform” rating on the stock in a research report on Thursday, August 15th. Cantor Fitzgerald reiterated a “neutral” rating on shares of bluebird bio in a research note on Monday, September 16th. Finally, Bank of America decreased their price target on bluebird bio from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Thursday, August 15th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $4.63.

bluebird bio Trading Down 3.8 %

BLUE opened at $0.48 on Friday. The company has a quick ratio of 0.57, a current ratio of 0.68 and a debt-to-equity ratio of 0.37. bluebird bio has a 52 week low of $0.45 and a 52 week high of $5.53. The stock has a market cap of $52.50 million, a PE ratio of -0.65 and a beta of 0.75. The business has a 50 day moving average of $0.54 and a 200-day moving average of $0.84.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Friday, September 13th. The biotechnology company reported ($0.36) EPS for the quarter. The firm had revenue of $18.57 million for the quarter. bluebird bio had a negative net margin of 567.29% and a negative return on equity of 207.25%. Equities research analysts predict that bluebird bio will post -1.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On bluebird bio

Several large investors have recently made changes to their positions in BLUE. Allegheny Financial Group LTD bought a new position in bluebird bio during the second quarter valued at approximately $25,000. Sequoia Financial Advisors LLC boosted its position in shares of bluebird bio by 48.0% during the 1st quarter. Sequoia Financial Advisors LLC now owns 40,085 shares of the biotechnology company’s stock valued at $51,000 after acquiring an additional 13,000 shares during the last quarter. Bayesian Capital Management LP purchased a new position in shares of bluebird bio in the first quarter valued at $52,000. Price T Rowe Associates Inc. MD increased its position in bluebird bio by 113.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock worth $71,000 after purchasing an additional 29,113 shares during the last quarter. Finally, SG Americas Securities LLC raised its stake in bluebird bio by 458.8% during the first quarter. SG Americas Securities LLC now owns 80,032 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 65,710 shares in the last quarter. 87.43% of the stock is owned by institutional investors.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.